NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) and TherapeuticsMD (NASDAQ:TXMD – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.
Profitability
This table compares NRx Pharmaceuticals and TherapeuticsMD’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| NRx Pharmaceuticals | -691.81% | N/A | -63.92% |
| TherapeuticsMD | -6.64% | -1.09% | -0.78% |
Insider and Institutional Ownership
4.3% of NRx Pharmaceuticals shares are held by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are held by institutional investors. 6.4% of NRx Pharmaceuticals shares are held by insiders. Comparatively, 1.7% of TherapeuticsMD shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of current recommendations and price targets for NRx Pharmaceuticals and TherapeuticsMD, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| NRx Pharmaceuticals | 2 | 0 | 6 | 0 | 2.50 |
| TherapeuticsMD | 1 | 0 | 0 | 0 | 1.00 |
NRx Pharmaceuticals currently has a consensus target price of $34.50, indicating a potential upside of 1,349.58%. Given NRx Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts plainly believe NRx Pharmaceuticals is more favorable than TherapeuticsMD.
Risk & Volatility
NRx Pharmaceuticals has a beta of 2.11, suggesting that its share price is 111% more volatile than the S&P 500. Comparatively, TherapeuticsMD has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500.
Earnings & Valuation
This table compares NRx Pharmaceuticals and TherapeuticsMD”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| NRx Pharmaceuticals | $1.23 million | 83.78 | -$28.62 million | ($0.55) | -4.33 |
| TherapeuticsMD | $3.27 million | 6.16 | -$570,000.00 | $0.02 | 87.00 |
TherapeuticsMD has higher revenue and earnings than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.
About NRx Pharmaceuticals
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.
About TherapeuticsMD
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
